A 922500
Based on 31 publication(s) in Google Scholar
A 922500 (DGAT-1 Inhibitor 4a) is a potent, selective, and orally bioavailable diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC50s of 9 and 22 nM against human and mouse DGAT-1, respectively.
For research use only. We do not sell to patients.
- Purity: 99.33%
- CAS No.: 959122-11-3
- Formula: C26H24N2O4
- Molecular Weight:428.48
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) A 922500
More- Cancer Cell. 2026 Feb 9;44(2):383-404.e18. [Abstract]
- Cell Metab. 2020 Aug 4;32(2):229-242.e8. [Abstract]
- Cell Mol Immunol. 2025 Apr 7. [Abstract]
- Mol Cell. 2022 Aug 18;82(16):3030-3044.e8. [Abstract]
- Hepatology. 2016 Apr;63(4):1272-86. [Abstract]
- Nat Commun. 2024 Sep 27;15(1):8273. [Abstract]
- Nat Commun. 2020 Jun 11;11(1):2967. [Abstract]
- Adv Sci (Weinh). 2025 Jul 29:e05436. [Abstract]
- Adv Sci (Weinh). 2025 May 14:e2406150. [Abstract]
- Theranostics. 2024 Jun 1;14(9):3470-3485. [Abstract]
- Redox Biol. 2022 Oct:56:102452. [Abstract]
- Int J Biol Sci. 2022 Oct 18;18(16):6114-6128. [Abstract]
- J Colloid Interface Sci. 2026 Jul 15:714:140204. [Abstract]
- Cell Death Dis. 2025 Oct 7;16(1):715. [Abstract]
- Anal Chem. 2025 Jul 22;97(28):15393-15401. [Abstract]
- Front Immunol. 2022 Sep 2;13:942768. [Abstract]
- PLoS Pathog. 2025 Nov 11;21(11):e1013694. [Abstract]
- Int Immunopharmacol. 2024 Jun 24:138:112518. [Abstract]
- FASEB J. 2025 Nov 30;39(22):e71249. [Abstract]
- J Lipid Res. 2024 Nov 4:100692. [Abstract]
- J Biol Chem. 2024 Apr;300(4):107168. [Abstract]
- Sci Rep. 2023 Oct 29;13(1):18549. [Abstract]
- Clin Immunol. 2022 Jul:240:109056. [Abstract]
- J Virol. 2022 Jan 26;96(2):e0147321. [Abstract]
- Cell Signal. 2026 Jun:142:112454. [Abstract]
- Vet Res. 2026 May 9;57(1):72.
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Aug 22;1870(8):159683. [Abstract]
- bioRxiv. 2026 Mar 17.
- Res Sq. 2025 Apr 24:rs.3.rs-6506954. [Abstract]
- bioRxiv. 2024 June 12.
- bioRxiv. 2023 Jul 3.
-
WB
-
IF
-
IF
Biological Activity
IC50: 9 nM (human DGAT-1), 22 nM (mouse DGAT-1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
0.007 μM
Compound: 4a
|
Inhibition of human recombinant DGAT1 expressed in Sf9 cells
Inhibition of human recombinant DGAT1 expressed in Sf9 cells
|
[PMID: 18183944] |
| Sf9 | IC50 |
0.024 μM
Compound: 4a
|
Inhibition of mouse recombinant DGAT1 expressed in Sf9 cells
Inhibition of mouse recombinant DGAT1 expressed in Sf9 cells
|
[PMID: 18183944] |
| Sf9 | IC50 |
20 nM
Compound: 4
|
Inhibition of human DGAT1 expressed in Sf9 cells assessed as formation of didecanoylglycerol product after 1 hr using 14C-decanoyl-CoA by beta scintillation counter
Inhibition of human DGAT1 expressed in Sf9 cells assessed as formation of didecanoylglycerol product after 1 hr using 14C-decanoyl-CoA by beta scintillation counter
|
[PMID: 21868220] |
A 922500 (A-922500) demonstrates excellent selectivity over other acyltransferases, including DGAT-2 (IC50=53 μM) and the phylogenetic family members acyl coenzyme A cholesterol acyltransferase-1 and -2 (IC50=296 μM) [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 959122-11-3
-
Appearance Solid
-
Molecular Weight 428.48
-
Formula C26H24N2O4
-
Color Off-white to yellow
-
SMILES
O=C(NC1=CC=C(C2=CC=C(C([C@@H]3CCC[C@H]3C(O)=O)=O)C=C2)C=C1)NC4=CC=CC=C4
-
Synonyms
DGAT-1 Inhibitor 4a
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (31)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. [Abstract]2026 Feb 9;44(2):383-404.e18. PMID: 41544627 -
Cell Metab
Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress. [Abstract]2020 Aug 4;32(2):229-242.e8. PMID: 32559414
A 922500 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2020 Aug 4;32(2):229-242.e8. [Abstract]
Effects of Butyrate (But, 1 mM), Valproate (Vpa, 5 mM) and Vorinostat (Vor, 1 μM) on the expression of P-gp and BCRP, NF-кB p65 and phosphorylated p65 (p-p65), and IкBα and phosphorylated IкBα (p-IкBα).
A 922500 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2020 Aug 4;32(2):229-242.e8. [Abstract]
Representative fluorescence imaging and quantification of ROS in U251 cells treated with DGAT1 inhibitor A-922500 (20 mg/mL) for 24 h or shRNA for 48 h in the presence or absence of the CPT1 inhibitor Etomoxir (ETO, 6 mM).
-
Cell Mol Immunol
2025 Apr 7. PMID: 40195475 -
Mol Cell
An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. [Abstract]2022 Aug 18;82(16):3030-3044.e8. PMID: 35764091 -
Hepatology
Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. [Abstract]2016 Apr;63(4):1272-86. PMID: 26698170 -
Nat Commun
Lipid droplets sequester palmitic acid to disrupt endothelial ciliation and exacerbate atherosclerosis in male mice. [Abstract]2024 Sep 27;15(1):8273. PMID: 39333556 -
Nat Commun
2020 Jun 11;11(1):2967. PMID: 32528049
A 922500 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Jun 11;11(1):2967. [Abstract]
The spatiotemporal distribution of LD is analyzed 5 dpi by immunofluorescence. Compared to DMSO control, cells treated with A922500 (DGAT1i) harbor only scarce LDs. Both the number and average volume of LDs are significantly reduced in the presence of DGAT1i.
-
Adv Sci (Weinh)
2025 Jul 29:e05436. PMID: 40726407 -
Adv Sci (Weinh)
Lipid Droplet-Derived Biomimetic Nanocarriers for the Enhancement of Porcine Intermuscular Fat Content. [Abstract]2025 May 14:e2406150. PMID: 40365640 -
Theranostics
GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. [Abstract]2024 Jun 1;14(9):3470-3485. PMID: 38948063 -
Redox Biol
Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/DGAT1 pathway and inhibiting M2 macrophage polarization. [Abstract]2022 Oct:56:102452. PMID: 36084349 -
Int J Biol Sci
Stearoyl-CoA Desaturase-1 dependent lipid droplets accumulation in cancer-associated fibroblasts facilitates the progression of lung cancer. [Abstract]2022 Oct 18;18(16):6114-6128. PMID: 36439884 -
J Colloid Interface Sci
Dual metabolic reprogramming by metal-polyphenol nanoplatform enhances ferroptotic therapy for triple-negative breast cancer. [Abstract]2026 Jul 15:714:140204. PMID: 41780429 -
Cell Death Dis
Fatty acid synthase-mediated lipid droplet formation enhances macrophage killing of Staphylococcus aureus. [Abstract]2025 Oct 7;16(1):715. PMID: 41057302 -
Anal Chem
2025 Jul 22;97(28):15393-15401. PMID: 40557718 -
Front Immunol
Integrated multi-omics reveals the activated retinal microglia with intracellular metabolic reprogramming contributes to inflammation in STZ-induced early diabetic retinopathy. [Abstract]2022 Sep 2;13:942768. PMID: 36119084 -
PLoS Pathog
Epstein-Barr virus-transformed B-cells from a hypoxia model of the germinal center requires external unsaturated fatty acids. [Abstract]2025 Nov 11;21(11):e1013694. PMID: 41218077 -
Int Immunopharmacol
Targeting lipid peroxidation-associated ferroptosis suppresses lung carcinoma progression by regulating cell cycle arrest. [Abstract]2024 Jun 24:138:112518. PMID: 38917528 -
FASEB J
FOXA1 Upregulates HILPDA to Enhance Lipid Droplet Accumulation and Anoikis Resistance in Lung Adenocarcinoma. [Abstract]2025 Nov 30;39(22):e71249. PMID: 41246996 -
J Lipid Res
Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells. [Abstract]2024 Nov 4:100692. PMID: 39505261 -
J Biol Chem
Neuroinvasive virus facilitates viral replication by employing lipid droplets to reduce arachidonic acid-induced ferroptosis. [Abstract]2024 Apr;300(4):107168. PMID: 38490434 -
Sci Rep
Lipidome and metabolome analyses reveal metabolic alterations associated with MCF-7 apoptosis upon 4-hydroxytamoxifen treatment. [Abstract]2023 Oct 29;13(1):18549. PMID: 37899460 -
Clin Immunol
The pro-inflammatory effect of triglyceride on human CD4+ T cells and experimental autoimmune uveitis. [Abstract]2022 Jul:240:109056. PMID: 35659924 -
J Virol
Lipid Droplets Are Beneficial for Rabies Virus Replication by Facilitating Viral Budding. [Abstract]2022 Jan 26;96(2):e0147321. PMID: 34757839 -
Cell Signal
2026 Jun:142:112454. PMID: 41765311 -
-
Biochim Biophys Acta Mol Cell Biol Lipids
Modulation of lipid droplet biogenesis by p38 MAPK and caspase-1 in docosahexaenoic acid-induced EA.hy926 endothelial cell apoptosis. [Abstract]2025 Aug 22;1870(8):159683. PMID: 40850528 -
-
Res Sq
Epstein-Barr Virus-Driven B-Cell Transformation under Germinal Center Hypoxia Requires External Unsaturated Fatty Acids. [Abstract]2025 Apr 24:rs.3.rs-6506954. PMID: 40313738 -
-
Solvent & Solubility
DMSO : ≥ 50 mg/mL (116.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 6.67 mg/mL (15.57 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice and Hamsters[1]
Thirteen-week-old male Golden Syrian hamsters (n=40), initially weighing approximately 140 g, are used. Ten-week-old Male Zucker fatty rats (n=32), weighing between 270 and 330 g, are used. After collection of baseline lipid profiles, hyperlipidemic hamsters (n=10/group) and Zucker fatty rats (n=8/group) are administered vehicle [20:80 (v/v), polyethylene glycol/hydroxypropyl-β-cyclodextrin (10% w/v)] or DGAT-1 inhibitor A 922500 (A-922500) at 0.03, 0.3, and 3 mg/kg, once daily by oral gavage. The dosing volume is 5 mL/kg. Serum lipid profiles are then measured 3 h after the dose on day 7 and day 14. Hamsters continue to be fed a high-fat diet with 10% fructose in the drinking water throughout the treatment period. Zucker fatty rats remain on standard rodent diet throughout the study.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (564 KB)
- English - EN (564 KB)
- Français - FR (564 KB)
- Deutsch - DE (564 KB)
- Norwegian - NO (564 KB)
- Español - ES (564 KB)
- Swedish - SV (564 KB)
- Italian - IT (564 KB)
- Korean - KR (564 KB)
- Portuguese - PT (564 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3338 mL | 11.6692 mL | 23.3383 mL | 58.3458 mL |
| 5 mM | 0.4668 mL | 2.3338 mL | 4.6677 mL | 11.6692 mL | |
| 10 mM | 0.2334 mL | 1.1669 mL | 2.3338 mL | 5.8346 mL | |
| 15 mM | 0.1556 mL | 0.7779 mL | 1.5559 mL | 3.8897 mL | |
| 20 mM | 0.1167 mL | 0.5835 mL | 1.1669 mL | 2.9173 mL | |
| 25 mM | 0.0934 mL | 0.4668 mL | 0.9335 mL | 2.3338 mL | |
| 30 mM | 0.0778 mL | 0.3890 mL | 0.7779 mL | 1.9449 mL | |
| 40 mM | 0.0583 mL | 0.2917 mL | 0.5835 mL | 1.4586 mL | |
| 50 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL | 1.1669 mL | |
| 60 mM | 0.0389 mL | 0.1945 mL | 0.3890 mL | 0.9724 mL | |
| 80 mM | 0.0292 mL | 0.1459 mL | 0.2917 mL | 0.7293 mL | |
| 100 mM | 0.0233 mL | 0.1167 mL | 0.2334 mL | 0.5835 mL |